Infectious Complications, Associated Factors, and Prognosis After Esophagectomy for Cancer: A French, Multicenter, Retrospective Study - CIFO-study

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

Infectious complications represent the most common postoperative adverse events following esophagectomy for cancer, such as pneumonia (15% of cases). These complications increase immediate risks, lengthen hospital stays, and worsen patient quality of life. The population includes patients admitted to intensive care after esophagectomy for cancer between January 1, 2017, and December 31, 2024. The study focuses on this population due to the increasing incidence of esophageal cancer, the increased use of surgery for these indications, and the importance of postoperative infections in these complex procedures, despite their understudied nature in the current literature. Identifying modifiable risk factors could lead to corrective measures and thus improve the prognosis of postoperative patients. The research focuses primarily on the incidence, types, factors, and prognosis associated with the occurrence of infections after esophagectomy for cancer. It also includes an analysis of the pathogens involved, their resistance profiles, and the antibiotic therapies used in first-line probabilistic treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients over 18 years of age

• Underwent esophagectomy for cancer between January 1, 2017, and December 31, 2024

• Scheduled admission to intensive care for postoperative monitoring

Locations
Other Locations
France
Hôpital Saint-Louis - APHP
RECRUITING
Paris
Saint Louis Hospital
NOT_YET_RECRUITING
Paris
Contact Information
Primary
François DEPRET, MD-PHD
francois.depret@aphp.fr
0142499570
Time Frame
Start Date: 2025-08-27
Estimated Completion Date: 2025-10-28
Participants
Target number of participants: 350
Related Therapeutic Areas
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov